Free Trial

Chemed Co. (NYSE:CHE) Shares Sold by Fuller & Thaler Asset Management Inc.

Chemed logo with Medical background

Fuller & Thaler Asset Management Inc. trimmed its position in Chemed Co. (NYSE:CHE - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,224 shares of the company's stock after selling 7,765 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 0.25% of Chemed worth $19,721,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CHE. Norges Bank purchased a new position in shares of Chemed in the 4th quarter valued at $95,872,000. Raymond James Financial Inc. acquired a new position in shares of Chemed during the fourth quarter worth about $42,023,000. FMR LLC boosted its position in shares of Chemed by 18.9% in the fourth quarter. FMR LLC now owns 283,790 shares of the company's stock worth $150,352,000 after buying an additional 45,174 shares during the period. Principal Financial Group Inc. grew its stake in shares of Chemed by 114.1% in the fourth quarter. Principal Financial Group Inc. now owns 74,658 shares of the company's stock valued at $39,554,000 after buying an additional 39,791 shares in the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new position in Chemed during the 4th quarter worth approximately $12,880,000. Hedge funds and other institutional investors own 95.85% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank of Canada boosted their price objective on shares of Chemed from $667.00 to $674.00 and gave the stock an "outperform" rating in a report on Monday. StockNews.com upgraded Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th.

Read Our Latest Stock Report on Chemed

Chemed Price Performance

CHE traded down $2.05 during trading on Wednesday, hitting $572.91. The company had a trading volume of 32,510 shares, compared to its average volume of 98,793. The company has a market cap of $8.37 billion, a PE ratio of 28.95, a P/E/G ratio of 2.15 and a beta of 0.49. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $623.61. The business has a 50-day moving average of $588.34 and a 200-day moving average of $566.62.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $646.94 million during the quarter, compared to the consensus estimate of $641.78 million. During the same period last year, the firm earned $5.20 earnings per share. The company's revenue for the quarter was up 9.8% compared to the same quarter last year. Research analysts forecast that Chemed Co. will post 21.43 earnings per share for the current year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $2.00 annualized dividend and a yield of 0.35%. Chemed's payout ratio is 9.74%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $593.67, for a total value of $1,187,340.00. Following the transaction, the chief executive officer now owns 102,679 shares of the company's stock, valued at $60,957,441.93. This trade represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.29% of the stock is owned by corporate insiders.

Chemed Company Profile

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Should You Invest $1,000 in Chemed Right Now?

Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines